“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial looking at ATN-224 and exemestane for breast cancer that is advanced or has come back after treatment in women who are past their menopause
This trial was looking at adding ATN-224 to hormone therapy for breast cancer that had spread to another part of the body or had come back after treatment. It was for women who had hormone receptor positive breast cancer. This trial was supported by Cancer Research UK.
Doctors often use hormone therapy to treat breast cancer. Exemestane is a type of hormone drug called an
ATN-224 is an anti angiogenic drug. This means it stops the cancer forming its own blood vessels. The drug works by binding to copper in the body. Cancer cells need copper to grow new blood vessels. So if there is less copper, the cancer cannot form new blood vessels. This will not directly kill cancer cells, but it may stop or slow down their growth.
In this trial, researchers were looking at exemestane and ATN-224 to see if this combination of drugs helped women with breast cancer.
The aims of the trial were to
- See if exemestane and ATN-224 was better than exemestane alone for advanced hormone receptor positive breast cancer
- Learn more about how ATN-224 works
- Find out more about the side effects
Summary of results
This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Adrian Harris
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)